CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al.
Biosimilars and the future of more affordable treatment for hematologic malignancies